Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Economic Aspects of the Development of New Medicines
1 January 1981
A lecture, on the economics of developing new drugs, particularly in relation to whether this should be a national or private enterprise. I have chosen to…
Health Research in England: Topic for Debate
1 January 1981
This paper is derived from the proceedings of an Office of Health Economics Study Day, held at the Royal College of Obstetricians and Gynaecology on 11…
Health Care Research Expenditure
1 June 1978
In the financial year 1976-77 over £220 million was spent on health care research in the United Kingdom. Taking account of recent expenditure growth and making…
Innovation in Industry: a Factor for Growth
1 July 1969
Over the past few years there has been a growing concern with Britain’s record of industrial innovation based upon technology. This stems from two factors. Firstly,…
Pharmaceutical Research: the Case for Growth in Britain
1 July 1967
ONE of the problems in Britain today is that too little of its academic research is associated with successful innovation in industry. The result is that…
Science, Industry in the State
7 January 1965
Based on a series of six lectures discussing some of the special considerations which arise when a science based industry has the government as a major…
Finance of Medical Research
7 January 1964
The explosive progress of medical science during the past twenty-five years has brought about a revolution in the health of the community and in the problems…